Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business UpdateSOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions
